• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症驱动基因和补偿性突变的深层系统发育

Deep phylogeny of cancer drivers and compensatory mutations.

作者信息

Rochman Nash D, Wolf Yuri I, Koonin Eugene V

机构信息

National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, 20894, USA.

出版信息

Commun Biol. 2020 Oct 2;3(1):551. doi: 10.1038/s42003-020-01276-7.

DOI:10.1038/s42003-020-01276-7
PMID:33009502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7532533/
Abstract

Driver mutations (DM) are the genetic impetus for most cancers. The DM are assumed to be deleterious in species evolution, being eliminated by purifying selection unless compensated by other mutations. We present deep phylogenies for 84 cancer driver genes and investigate the prevalence of 434 DM across gene-species trees. The DM are rare in species evolution, and 181 are completely absent, validating their negative fitness effect. The DM are more common in unicellular than in multicellular eukaryotes, suggesting a link between these mutations and cell proliferation control. 18 DM appear as the ancestral state in one or more major clades, including 3 among mammals. We identify within-gene, compensatory mutations for 98 DM and infer likely interactions between the DM and compensatory sites in protein structures. These findings elucidate the evolutionary status of DM and are expected to advance the understanding of the functions and evolution of oncogenes and tumor suppressors.

摘要

驱动突变(DM)是大多数癌症的遗传推动力。在物种进化中,驱动突变被认为是有害的,除非有其他突变进行补偿,否则会通过纯化选择被消除。我们展示了84个癌症驱动基因的深度系统发育树,并研究了434个驱动突变在基因-物种树上的普遍性。驱动突变在物种进化中很罕见,其中181个完全不存在,证实了它们对适应性的负面影响。驱动突变在单细胞真核生物中比在多细胞真核生物中更常见,这表明这些突变与细胞增殖控制之间存在联系。18个驱动突变在一个或多个主要分支中表现为祖先状态,其中包括3个在哺乳动物中的突变。我们识别出98个驱动突变的基因内补偿性突变,并推断出驱动突变与蛋白质结构中补偿位点之间可能的相互作用。这些发现阐明了驱动突变的进化状态,有望促进对癌基因和肿瘤抑制基因功能及进化的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/5eaa35a5cacc/42003_2020_1276_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/7b2142b434ae/42003_2020_1276_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/febd8bfc0158/42003_2020_1276_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/7e9397a78b4d/42003_2020_1276_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/5059fb5c90f2/42003_2020_1276_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/b860a9c616b7/42003_2020_1276_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/5eaa35a5cacc/42003_2020_1276_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/7b2142b434ae/42003_2020_1276_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/febd8bfc0158/42003_2020_1276_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/7e9397a78b4d/42003_2020_1276_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/5059fb5c90f2/42003_2020_1276_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/b860a9c616b7/42003_2020_1276_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3729/7532533/5eaa35a5cacc/42003_2020_1276_Fig6_HTML.jpg

相似文献

1
Deep phylogeny of cancer drivers and compensatory mutations.癌症驱动基因和补偿性突变的深层系统发育
Commun Biol. 2020 Oct 2;3(1):551. doi: 10.1038/s42003-020-01276-7.
2
The molecular evolution of cancer associated genes in mammals.癌症相关基因在哺乳动物中的分子进化。
Sci Rep. 2024 May 22;14(1):11650. doi: 10.1038/s41598-024-62425-0.
3
Identifying Epistasis in Cancer Genomes: A Delicate Affair.鉴定癌症基因组中的上位效应:精细活。
Cell. 2019 May 30;177(6):1375-1383. doi: 10.1016/j.cell.2019.05.005.
4
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.酪氨酸激酶突变热点的致癌特征的进化支持癌症的返祖假说。
Sci Rep. 2018 May 29;8(1):8256. doi: 10.1038/s41598-018-26653-5.
5
Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.机器学习分类和癌症突变的结构-功能分析揭示了癌基因和肿瘤抑制基因中驱动位点的独特动态和网络特征。
J Chem Inf Model. 2018 Oct 22;58(10):2131-2150. doi: 10.1021/acs.jcim.8b00414. Epub 2018 Oct 3.
6
Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.通过EST序列分析检测到的人类癌症中体细胞突变的正选择迹象。
BMC Cancer. 2006 Feb 9;6:36. doi: 10.1186/1471-2407-6-36.
7
Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.癌基因和肿瘤抑制基因中突变热点的鉴定与分析。
Oncotarget. 2017 Mar 28;8(13):21290-21304. doi: 10.18632/oncotarget.15514.
8
Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.利用癌症突变的预测功能影响揭示癌症中的选择。在癌症驱动基因的鉴定中的应用。
BMC Genomics. 2013;14 Suppl 3(Suppl 3):S8. doi: 10.1186/1471-2164-14-S3-S8. Epub 2013 May 28.
9
SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.SomInaClust:基于失活和聚类的体细胞突变模式检测癌症基因。
BMC Bioinformatics. 2015 Apr 23;16:125. doi: 10.1186/s12859-015-0555-7.
10
Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.对哺乳动物 p53 的最大似然分析表明,在纯化部位存在正选择的位点和更高的致瘤性突变。
Gene. 2011 Sep 1;483(1-2):29-35. doi: 10.1016/j.gene.2011.05.011. Epub 2011 May 24.

引用本文的文献

1
MutationAssessor in cBioPortal.cbioportal 中的突变评估器。
bioRxiv. 2025 Aug 12:2025.08.10.669566. doi: 10.1101/2025.08.10.669566.
2
Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins.癌症中后生动物基因调控网络的破坏改变了单细胞和多细胞起源基因之间的共表达平衡。
Genome Biol. 2024 Apr 29;25(1):110. doi: 10.1186/s13059-024-03247-1.
3
Coordinated evolution at amino acid sites of SARS-CoV-2 spike.SARS-CoV-2 刺突蛋白上氨基酸位点的协调进化。

本文引用的文献

1
The Molecular Control of Calcitonin Receptor Signaling.降钙素受体信号传导的分子调控
ACS Pharmacol Transl Sci. 2019 Jan 11;2(1):31-51. doi: 10.1021/acsptsci.8b00056. eCollection 2019 Feb 8.
2
Identifying Epistasis in Cancer Genomes: A Delicate Affair.鉴定癌症基因组中的上位效应:精细活。
Cell. 2019 May 30;177(6):1375-1383. doi: 10.1016/j.cell.2019.05.005.
3
In silico learning of tumor evolution through mutational time series.通过突变时间序列进行肿瘤进化的计算学习。
Elife. 2023 Feb 8;12:e82516. doi: 10.7554/eLife.82516.
4
It takes a village to build a virus.构建一种病毒需要各方协作。
Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2219052120. doi: 10.1073/pnas.2219052120. Epub 2023 Jan 26.
5
Molecular adaptations during viral epidemics.病毒流行期间的分子适应。
EMBO Rep. 2022 Aug 3;23(8):e55393. doi: 10.15252/embr.202255393. Epub 2022 Jul 18.
6
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.变构作用:变构致癌驱动因子和创新变构药物。
J Mol Biol. 2022 Sep 15;434(17):167569. doi: 10.1016/j.jmb.2022.167569. Epub 2022 Apr 1.
7
Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.SARS-CoV-2 受体结合域界面的上位性作用及对疫苗逃逸的有利影响
mBio. 2022 Apr 26;13(2):e0013522. doi: 10.1128/mbio.00135-22. Epub 2022 Mar 15.
8
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合域(RBD)界面处的上位性及其对疫苗逃逸的平淡无奇的影响
bioRxiv. 2021 Dec 22:2021.08.30.458225. doi: 10.1101/2021.08.30.458225.
9
Ongoing global and regional adaptive evolution of SARS-CoV-2.SARS-CoV-2 在全球和区域范围内持续的适应性进化。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2104241118. Epub 2021 Jul 2.
10
Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)正在进行的全球和区域适应性进化
bioRxiv. 2021 Mar 2:2020.10.12.336644. doi: 10.1101/2020.10.12.336644.
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9501-9510. doi: 10.1073/pnas.1901695116. Epub 2019 Apr 23.
4
Origins and Evolution of the Global RNA Virome.全球 RNA 病毒组的起源与演化。
mBio. 2018 Nov 27;9(6):e02329-18. doi: 10.1128/mBio.02329-18.
5
Criticality in tumor evolution and clinical outcome.肿瘤进化和临床结局中的关键问题。
Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11101-E11110. doi: 10.1073/pnas.1807256115. Epub 2018 Nov 7.
6
The EVcouplings Python framework for coevolutionary sequence analysis.EVcouplings Python 框架用于共进化序列分析。
Bioinformatics. 2019 May 1;35(9):1582-1584. doi: 10.1093/bioinformatics/bty862.
7
Cancer-mutation network and the number and specificity of driver mutations.癌症突变网络和驱动突变的数量和特异性。
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6010-E6019. doi: 10.1073/pnas.1803155115. Epub 2018 Jun 12.
8
The yin and yang of solubilization and stabilization for wild-type and full-length membrane protein.野生型和全长膜蛋白的增溶和稳定的阴阳两面。
Methods. 2018 Sep 1;147:118-125. doi: 10.1016/j.ymeth.2018.02.017. Epub 2018 Feb 23.
9
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.RGS7 在黑色素瘤中经常发生突变,促进人类癌细胞的迁移和侵袭。
Sci Rep. 2018 Jan 12;8(1):653. doi: 10.1038/s41598-017-18851-4.
10
Epistasis in genomic and survival data of cancer patients.癌症患者基因组和生存数据中的上位性
PLoS Comput Biol. 2017 Jul 5;13(7):e1005626. doi: 10.1371/journal.pcbi.1005626. eCollection 2017 Jul.